Glycopyrronium Bromide Mercurypharm Ltd

Glycopyrronium bromide supplied by Mercurypharm Ltd is an anticholinergic (muscarinic antagonist) medication administered by intramuscular or intravenous injection. It is classified under ATC code R03BB02 and is prescribed in the European Union for pre‑operative and peri‑operative management of secretions and for certain cardiac indications.

Glycopyrronium bromide is used in clinical practice to control excessive secretions and support cardiac function in specific settings.

- Reduction of salivary secretions during surgery to improve airway management. - Decrease of respiratory tract secretions in peri‑operative patients. - Adjunct therapy for bronchospasm associated with anesthesia. - Management of intra‑operative bradycardia when other agents are unsuitable. - Facilitation of endotracheal intubation by minimizing oral and pharyngeal secretions.

Side effects of glycopyrronium bromide vary in frequency and severity.

Common: - Dry mouth (xerostomia). - Throat irritation. - Mild tachycardia. - Transient facial flushing. - Nausea. - Dizziness.

Serious: - Severe tachyarrhythmias. - Acute urinary retention. - Angle‑closure glaucoma. - Anaphylactic reaction. - Prolonged bronchospasm. - Persistent hypotension.

When prescribing glycopyrronium bromide, clinicians should consider several safety aspects.

- Assess for a history of glaucoma, especially narrow‑angle type. - Use caution in patients with urinary retention or prostatic hypertrophy. - Monitor heart rate and rhythm in individuals with cardiac disease. - Evaluate renal and hepatic function before dosing, as impairment may affect clearance. - Avoid in patients with known hypersensitivity to anticholinergic agents. - Consider dose adjustment in elderly patients due to increased sensitivity to anticholinergic effects.

Glycopyrronium bromide may interact with other medications, influencing its safety and efficacy.

Avoid: - Concurrent use with other anticholinergic drugs (e.g., atropine, scopolamine) that may exacerbate dry mouth and tachycardia. - Combination with beta‑blockers in patients prone to bradycardia. - Co‑administration with drugs that prolong QT interval.

Use with caution: - Opioid analgesics, as reduced secretions may mask signs of respiratory depression. - Diuretics, due to potential additive effects on electrolyte balance. - Anesthetic agents that have cholinergic activity. - Medications affecting renal excretion, such as aminoglycosides.